Vergote I - Search Results

1

Radio-immunotargeting in experimental animal models of intraperitoneal cancer.

Fjeld JG, Vergote I, De Vos L, Nustad K. Fjeld JG, et al. Among authors: vergote i. Acta Obstet Gynecol Scand Suppl. 1992;155:105-11. doi: 10.1111/j.1600-0412.1992.tb00015.x. Acta Obstet Gynecol Scand Suppl. 1992. PMID: 1502887 Review.

2

Distribution of intraperitoneally injected microspheres labeled with the alpha-emitter astatine (211At) compared with phosphorus (32P) and yttrium (90Y) colloids in mice.

Vergote I, Larsen RH, De Vos L, Winderen M, Ellingsen T, Bjørgum J, Hoff P, Aas M, Tropé C, Nustad K. Vergote I, et al. Gynecol Oncol. 1992 Dec;47(3):358-65. doi: 10.1016/0090-8258(92)90140-e. Gynecol Oncol. 1992. PMID: 1473750

3

Therapeutic efficacy of the alpha-emitter 211At bound on microspheres compared with 90Y and 32P colloids in a murine intraperitoneal tumor model.

Vergote I, Larsen RH, de Vos L, Nesland JM, Bruland O, Bjørgum J, Alstad J, Tropé C, Nustad K. Vergote I, et al. Gynecol Oncol. 1992 Dec;47(3):366-72. doi: 10.1016/0090-8258(92)90141-5. Gynecol Oncol. 1992. PMID: 1473751

4

B-cell hybridoma as intraperitoneal tumor model: correlation between tumor growth and monoclonal antibody production.

Vergote I, De Vos L, Fjeld J, Nesland J, Kierulf B, Michaelsen T, Nustad K. Vergote I, et al. Hybridoma. 1992 Jun;11(3):323-31. doi: 10.1089/hyb.1992.11.323. Hybridoma. 1992. PMID: 1500068

5

CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma.

Vergote IB, Abeler VM, Børmer OP, Stigbrand T, Tropé C, Nustad K. Vergote IB, et al. Tumour Biol. 1992;13(3):168-74. doi: 10.1159/000217761. Tumour Biol. 1992. PMID: 1626181

6

Intraperitoneal antineoplastic agents in the management of ovarian cancer.

Tropé C, Kaern J, Vergote I. Tropé C, et al. Among authors: vergote i. Eur J Surg Suppl. 1991 May;(561):83-6. Eur J Surg Suppl. 1991. PMID: 1720054 Review. No abstract available.

7

Placental alkaline phosphatase as a tumor marker in ovarian cancer.

Vergote I, Onsrud M, Nustad K. Vergote I, et al. Obstet Gynecol. 1987 Feb;69(2):228-32. Obstet Gynecol. 1987. PMID: 3808507

8

Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model.

Larsen RH, Hoff P, Vergote IB, Bruland OS, Aas M, De Vos L, Nustad K. Larsen RH, et al. Among authors: vergote ib. Gynecol Oncol. 1995 Apr;57(1):9-15. doi: 10.1006/gyno.1995.1093. Gynecol Oncol. 1995. PMID: 7705707

9

Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse.

Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN, Tropé CG. Vergote IB, et al. Am J Obstet Gynecol. 1993 Jul;169(1):40-52. doi: 10.1016/0002-9378(93)90129-7. Am J Obstet Gynecol. 1993. PMID: 8333474

10

Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second-look laparotomy.

Vergote IB, Winderen M, De Vos LN, Tropé CG. Vergote IB, et al. Cancer. 1993 Apr 1;71(7):2250-60. doi: 10.1002/1097-0142(19930401)71:7<2250::aid-cncr2820710715>3.0.co;2-#. Cancer. 1993. PMID: 8453546 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

888 results

Search Page

Filters